GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Notes Receivable

Celldex Therapeutics (STU:TCE2) Notes Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Notes Receivable?

Celldex Therapeutics's Notes Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Celldex Therapeutics Notes Receivable Historical Data

The historical data trend for Celldex Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Notes Receivable Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Celldex Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Celldex Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Celldex Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (STU:TCE2) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines